- Home
- BACQ vs AVIR Comparison
BACQ vs AVIR Comparison
Compare BACQ & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BACQ
- AVIR
- Stock Information
- Founded
- BACQ 2024
- AVIR 2012
- Country
- BACQ United States
- AVIR United States
- Employees
- BACQ N/A
- AVIR N/A
- Industry
- BACQ
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- BACQ
- AVIR Health Care
- Exchange
- BACQ NYSE
- AVIR Nasdaq
- Market Cap
- BACQ 333.2M
- AVIR 273.7M
- IPO Year
- BACQ 2024
- AVIR 2020
- Fundamental
- Price
- BACQ $10.03
- AVIR $2.97
- Analyst Decision
- BACQ
- AVIR Hold
- Analyst Count
- BACQ 0
- AVIR 1
- Target Price
- BACQ N/A
- AVIR $6.00
- AVG Volume (30 Days)
- BACQ 211.0K
- AVIR 381.8K
- Earning Date
- BACQ 01-01-0001
- AVIR 05-13-2025
- Dividend Yield
- BACQ N/A
- AVIR N/A
- EPS Growth
- BACQ N/A
- AVIR N/A
- EPS
- BACQ N/A
- AVIR N/A
- Revenue
- BACQ N/A
- AVIR N/A
- Revenue This Year
- BACQ N/A
- AVIR N/A
- Revenue Next Year
- BACQ N/A
- AVIR N/A
- P/E Ratio
- BACQ $111.40
- AVIR N/A
- Revenue Growth
- BACQ N/A
- AVIR N/A
- 52 Week Low
- BACQ $9.80
- AVIR $2.60
- 52 Week High
- BACQ $10.07
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- BACQ N/A
- AVIR 51.96
- Support Level
- BACQ N/A
- AVIR $2.77
- Resistance Level
- BACQ N/A
- AVIR $2.98
- Average True Range (ATR)
- BACQ 0.00
- AVIR 0.21
- MACD
- BACQ 0.00
- AVIR 0.02
- Stochastic Oscillator
- BACQ 0.00
- AVIR 64.91
About BACQ BLEICHROEDER ACQUISITION CORP. I
Bleichroeder Acquisition Corp I is a blank check company.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).